Conatumumab Biosimilar - Research Grade

Human

TNFRSF10B

>1mg/ml

IgG1 - kappa

CHO Cells

Benufutamab Biosimilar - Research Grade (ICH5390), Drozitumab Biosimilar - Research Grade (ICH5491), Lexatumumab Biosimilar - Research Grade (ICH5640), Tigatuzumab Biosimilar - Research Grade (ICH5921), Tilogotamab Biosimilar - Research Grade (ICH5922)

https://www.imgt.org/mAb-DB/

ICH3002

O14763

Blue ice

This product is a research-grade biosimilar of conatumumab, supplied as an unconjugated, non-therapeutic analog of the originator molecule for research use only. It reproduces the antigen-binding specificity of conatumumab (also known as AMG 655), a fully human agonist monoclonal antibody of the IgG1 kappa class directed against human TNFRSF10B (death receptor 5; DR5/TRAIL-R2). Unlike the clinical originator, this reagent is intended solely for in-vitro and functional laboratory investigation and is not a drug. It is manufactured to in-vivo research standards with low endotoxin, offered in bulk milligram-to-gram quantities, and is well suited to comparability, reference-standard, and mechanism-of-action studies. Because conatumumab acts as a receptor agonist that clusters DR5 to trigger apoptotic signaling, this biosimilar is a useful tool for interrogating TRAIL-pathway biology, benchmarking assay performance against a defined originator sequence, and supporting antibody characterization workflows. Typical applications include receptor-binding assays, agonist-driven apoptosis induction in tumor cell lines, and use as a positive control in DR5-targeting programs. Investigators should confirm suitability for their specific system. TNFRSF10B, more commonly called death receptor 5 (DR5) or TRAIL-R2, is a single-pass transmembrane member of the TNF receptor superfamily. It binds the cytotoxic ligand TRAIL (TNFSF10) and, upon ligand-induced or antibody-induced clustering, recruits the adaptor FADD and pro-caspase-8 through its cytoplasmic death domain to assemble the death-inducing signaling complex (DISC). DISC formation activates the caspase cascade and drives extrinsic-pathway apoptosis, a mechanism of particular interest in oncology because many tumor cells retain sensitivity to DR5 engagement. DR5 also contributes to NF-kappa-B activation and is important for endoplasmic-reticulum-stress-induced cell death. Because effective apoptotic signaling depends on higher-order receptor cross-linking, agonist antibodies such as conatumumab are studied both alone and with secondary cross-linking or FcgammaR-mediated clustering.

Death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL receptor 2, TRAIL-R2, Tumor necrosis factor receptor superfamily member 10B, DR5, KILLER, TRICK2, ZTNFR9

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Conatumumab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Conatumumab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Conatumumab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Conatumumab that binds TNFRSF10B; for research use only.